All In Biotech

Drug Trial Radar · NCT07105709

Open-label Extension Study in Participants With Early Alzheimer's Disease

A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Aug 14, 2025

Primary completion

Sep 15, 2028

Study completion Dec 8, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Alector Inc.
First posted
Aug 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment \[MCI\] and mild dementia due to AD) who have completed the parent study.

Conditions

  • Alzheimer's Disease

Interventions

  • GSK4527226Drug

    GSK4527226 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (AEs) during the OLETime frame: Up to 112 Weeks
  2. Number of Participants with Adverse Event of Special Interest (AESIs) during the OLETime frame: Up to 112 Weeks
  3. Number of Participants with Serious Adverse Events (SAEs) during the OLETime frame: Up to 112 Weeks
  4. Number of Participants with Amyloid related imaging abnormalities (ARIAs) Including Severity during the OLETime frame: Up to 112 Weeks

Locations

33 sites in 11 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Maitland, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Stuart, Florida · Recruiting

  • GSK Investigational Site

    Toms River, New Jersey · Recruiting

  • GSK Investigational Site

    Staten Island, New York · Recruiting

  • GSK Investigational Site

    Matthews, North Carolina · Recruiting

  • GSK Investigational Site

    Oklahoma City, Oklahoma · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Fairfax, Virginia · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina · Recruiting

  • GSK Investigational Site

    Macquarie Park, New South Wales, Australia · Recruiting

  • GSK Investigational Site

    Nedlands, Western Australia, Australia · Recruiting

  • GSK Investigational Site

    Ottawa, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Peterborough, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Greenfield Park, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Sherbrooke, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Oulu, Finland · Recruiting

  • GSK Investigational Site

    Bergen, Norway · Recruiting

  • GSK Investigational Site

    Oslo, Norway · Recruiting

  • GSK Investigational Site

    Junggu, South Korea · Recruiting

  • GSK Investigational Site

    Barcelona, Spain · Recruiting

  • GSK Investigational Site

    Gothenburg, Sweden · Recruiting

  • GSK Investigational Site

    Malmö, Sweden · Recruiting

  • GSK Investigational Site

    Stockholm, Sweden · Recruiting

  • GSK Investigational Site

    Tainan, Taiwan · Recruiting

  • GSK Investigational Site

    Taoyuan, Taiwan · Recruiting

  • GSK Investigational Site

    Birmingham, United Kingdom · Recruiting

  • GSK Investigational Site

    Bristol, United Kingdom · Recruiting

  • GSK Investigational Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.